CytoDyn Inc.

Equities

CYDY

US23283M1018

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:23:08 2024-06-28 am EDT			5-day change	1st Jan Change
0.137 ^USD	-7.93%		-2.14%	-29.74%

Jun. 27	CytoDyn Inc. and SMC Laboratories, Inc. Announce Start of Preclinical MASH Study	CI
May. 30	Transcript : CytoDyn Inc. - Special Call

CytoDyn Inc. Announces Resignation of Michael A. Klump as Member of the Board

January 21, 2020 at 04:30 pm EST

CytoDyn Inc. announced that, on January 15, 2020, Michael A. Klump resigned as a member of the Board, effective immediately. Mr. Klump's resignation is not related to any known disagreement with the Company on any matters relating to its operations, policies or practices.

Latest news about CytoDyn Inc.

CytoDyn Inc. and SMC Laboratories, Inc. Announce Start of Preclinical MASH Study	Jun. 27	CI
Transcript : CytoDyn Inc. - Special Call	May. 30
CytoDyn Inc. announced that it has received $8.942 million in funding	May. 02	CI
CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 15	CI
Transcript : CytoDyn Inc. - Special Call	Mar. 05
CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma	Feb. 01	CI
Cytodyn Inc. Announces CFO Changes	Jan. 29	CI
CytoDyn Inc. Announces Appointment of Jacob Lalezari as CEO	Jan. 29	CI
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 16	CI
CytoDyn Inc. announced a financing transaction	Dec. 28	CI
Transcript : CytoDyn Inc. - Special Call	Dec. 14
CytoDyn Inc. Appoints Jacob Lalezari M.D. as Interim CEO	Nov. 21	CI
CytoDyn Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-23	CI
CytoDyn Inc. Reports Earnings Results for the Full Year Ended May 31, 2023	23-09-14	CI
Transcript : CytoDyn Inc. - Special Call	23-07-24
CytoDyn Inc. Announces CEO Changes	23-07-11	CI
CytoDyn Inc. Announces Executive Changes	23-07-11	CI
CytoDyn Inc. Announces Executive Changes	23-05-24	CI
Transcript : CytoDyn Inc. - Special Call	23-04-11
CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	23-04-10	CI
CytoDyn Inc. announced that it has received $4.899 million in funding	23-03-02	CI
CytoDyn Inc. announced that it expects to receive $7.866 million in funding	23-01-12	CI
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	23-01-09	CI
Transcript : CytoDyn Inc. - Special Call	22-12-29
MarketScreener's World Press Review: December 21, 2022	22-12-21

Chart CytoDyn Inc.

Duration

Period

More charts

Company Profile

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYTODYN INC.	-29.74%	157M
VERTEX PHARMACEUTICALS INCORPORATED	+16.11%	122B
REGENERON PHARMACEUTICALS, INC.	+19.29%	113B
ARGENX SE	+18.95%	26.49B
BIONTECH SE	-23.53%	19.4B
GENMAB A/S	-19.03%	16.24B
BEIGENE, LTD.	-20.15%	15.4B
WUXI APPTEC CO., LTD.	-46.14%	15.15B
SAREPTA THERAPEUTICS, INC.	+63.43%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+5.03%	13.52B

Bio Therapeutic Drugs